Found 11 resultsAuthor [ Title] Type Year
Filters: Author is Mulligan, MJ [Clear All Filters]
“Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines”, J Infec Dis, vol. 177, pp. 310-319, 1998.,
“Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Response.”, in ID Week 2014, Philadelphia, PA, 2014.,
“A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8+ Cytotoxic T Lymphocyte Responses in Seronegative Volunteers”, J Infec Dis, vol. 180, no. 2, pp. 290-298, 1999.,
“Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group”, AIDS Res HumRetroviruses, vol. 14, pp. 1365-74, 2000.
“Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons”, J Infect Dis, vol. 206, pp. 811-820, 2012.,
“Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine with MF59 Adjuvant: A Randomized Clinical Trial”, JAMA, vol. 312, pp. 1420-1428, 2014.,
“NIAID AIDS Vaccine Evaluation Group. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp 120 prime-boost HIV-1 vaccine”, AIDS Res HumRetroviruses, vol. 14, pp. 1365-74, 2000.
“Phase II Trial in Adults of Concurrent or Sequential 2009 Pandemic H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations”, Vaccine, vol. 33, pp. 163-173, 2015.,
“Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons >/=18 Years Old”, J Infect Dis, vol. 212, no. 4, pp. 552-561, 2015.,
“Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use with MF59 Adjuvant: A Randomized Clinical Trial”, JAMA, vol. 312, pp. 1409-1419, 2014.,